Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

Spyridon Dimitrios Chondropoulos; Annaliza Delastic; Alexras Spyridonidis

首页> 外文期刊>Memo - Magazine of European medical oncology >Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

【24h】

Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

机译：用抗CD33抗体靶向AML：历史演练，临床影响，未来方向

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In the past years, new emerging targeted therapies against specific markers have revolutionized the field of treating malignancies. In this article, we discuss the first available agent that targets a specific molecule in acute myeloid leukemia, as well as the future possibilities that genetic research unveil.

机译：在过去的几年中，针对特定标志物的新兴靶向疗法彻底改变了治疗恶性肿瘤的领域。在本文中，我们讨论了第一种针对急性髓性白血病中特定分子的药物，以及遗传研究的未来可能性。

著录项

来源
《Memo - Magazine of European medical oncology》 |2013年第4期|共4页
作者
Spyridon Dimitrios Chondropoulos; Annaliza Delastic; Alexras Spyridonidis;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions [J] . Spyridon Dimitrios Chondropoulos, Annaliza Delastic, Alexras Spyridonidis Memo - Magazine of European medical oncology . 2013,第4期

机译：用抗CD33抗体靶向AML：历史演练，临床影响，未来方向
2. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) [J] . Ravandi Farhad, Stein Anthony S., Kantarjian Hagop M., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AMG 330的第1阶段第一人体研究，抗CD33双特异性T细胞参录手（咬合（R））抗体构建体，复发/难治性急性髓性白血病（R / R AML）
3. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts [J] . Vasu Sumithira, He Shun, Cheney Carolyn, Blood: The Journal of the American Society of Hematology . 2016,第23期

机译：地西他滨增强抗CD33单克隆抗体BI 836858介导的针对AML爆炸的自然杀伤剂ADCC
4. Irregular-antibody screening in 29, 236 patients from Shandong region and clinical impact on blood transfusion [C] . Xianjun Ma, Zhonghua Chu 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：山东地区29例236例不定期抗体筛查及其对输血的临床影响
5. Volatility in the futures markets for financial and physical commodity assets: The impact of high frequency data on the distributional properties and forecasting of volatility, direction-of-change probability forecasting and asymmetric volatility effects. [D] . Georgiev, Georgi Y. 2007

机译：金融和实物商品资产的期货市场中的波动性：高频数据对分布特性和波动性预测，变化方向概率预测和非对称波动性影响的影响。
6. Bispecific Antibodies for Multiple Myeloma: A Review of Targets Drugs Clinical Trials and Future Directions [O] . Chiara Caraccio, Sachi Krishna, Darci J. Phillips, 2020

机译：多发性骨髓瘤双特异性抗体：靶药物临床试验和未来方向的审查。
7. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts [O] . Walter, Roland B., Boyle, Kelli M., Appelbaum, Frederick R., 2008

机译：同时靶向CD45会显着提高抗CD33免疫缀合物吉姆单抗ozogamicin对急性髓细胞白血病（AML）细胞的细胞毒性，并改善携带人AML异种移植物的小鼠的存活率
8. Health and Cost Impacts of a Maternal-Child Advocacy Program: Outcomes at TwelveMonths. A Clinical Trial Evaluating the REACH-Futures Program. Abstract. Executive Summary and Final Report [R] . Norr, K. F., Crittenden, K. S., Reyes, O., 1998

机译：母婴宣传计划对健康和成本的影响：十二个月的结果。评估REaCH-期货计划的临床试验。抽象。执行摘要和最终报告

Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

摘要

著录项

相似文献

相关主题

期刊订阅